Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Depreciation & Amortization (CF) (2020 - 2025)

Tango Therapeutics has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $500000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $500000.0 for Q4 2025, down 19.35% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (down 7.96% YoY), and the annual figure for FY2025 was $2.3 million, down 7.96%.
  • Depreciation & Amortization (CF) for Q4 2025 was $500000.0 at Tango Therapeutics, down from $553000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for TNGX hit a ceiling of $632000.0 in Q2 2024 and a floor of $200000.0 in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $573500.0 (2022), compared with a mean of $483500.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 119.53% in 2022 and later fell 19.35% in 2025.
  • Tango Therapeutics' Depreciation & Amortization (CF) stood at $256000.0 in 2021, then surged by 119.53% to $562000.0 in 2022, then rose by 9.43% to $615000.0 in 2023, then grew by 0.81% to $620000.0 in 2024, then fell by 19.35% to $500000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $500000.0 (Q4 2025), $553000.0 (Q3 2025), and $625000.0 (Q2 2025) per Business Quant data.